Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory clinical study

Inclusion criteria

Male subjects with molecular diagnosis of DMD aged 6-18 years who were willing to participate in the study with written informed consent.

Exclusion criteria

Patients with a previous (within the past 1 month) or concomitant participation in any other therapeutic trial; a known or suspected malignancy; any other chronic disease or clinically relevant limitation of renal, liver or heart function according to the discretion of the investigator.

Investigations

The following tests were carried out after written consent was obtained from the study subjects.

At baseline and at the end of the study (after 45 days)

• Background survey: gender, date of birth, age, habits, current medical history, medication, treatment, allergies (to drugs and food), regular use of food for specified health uses, functional foods, health foods, intake of foods rich in β-glucan foods containing beta-glucan and intake of immunity-boosting foods

• Medical history and physical measurements: height, weight, BMI, temperature

• Physiological examination: systolic blood pressure, diastolic blood pressure, pulse rate

• ECG

• Muscle strength test using MRC grading [10]

• Six-minute walk test (6MWT) [11]

• North Star Ambulatory Assessment (NSAA) [12]

• Blood sampling and investigations for the levels of IL-6, IL-13, TGF-β, creatinine kinase (CK), titin, haptoglobin, TNF-α, dystrophin, cystatin in the blood and myoglobin in the urine

• Subjects were contacted every week for drug compliance and recording of adverse effects, if any

Study subjects = 28

The study was designed as an exploratory study, so there were two intervention conditions: one control and one test group. As the minimum number of participants required for statistical comparisons within and between intervention conditions is four per intervention condition, a total of 28 target study participants (10 in treatment arm I [control] group and 18 in treatment arm II [N-163]) were used. One patient was disqualified due to misrepresentation of diagnosis. The CONSORT flow diagram of the trial is shown in Figure 1.

• Download figure
• Open in new tab

Figure 1:

CONSORT flow diagram of the trial

Selection of study subjects

Study investigators and other investigators included study subjects who had consented to participate in the study, met the selection criteria and not the exclusion criteria, and who were judged to have no problem participating in the study.

Allocation of study subjects

The person in charge of the allocation, as specified in the study protocol, allocated the study subjects to the two groups by simple randomization (1:2).

Primary outcome

Observation of changes in the levels of IL-6 in serum and myoglobin levels in urine from the baseline measured by ELISA.

Secondary outcome

• Observation of changes in the levels of IL-13, TGF-β, CK, titin, dystrophin, haptoglobin and cystatin C in the serum measured by ELISA.

• Observation of changes in the muscle function tests

• Monitoring for adverse effects

ELISA

The biomarkers were validated using sandwich enzyme immunoassay. ELISA kits were purchased from different manufacturers and the assay details along with sensitivity are listed in Table 2. ELISAs were performed according to manufacturer’s instructions and the serum was diluted to fall within the linear range of each respective assay.

Statistical analysis

All data were analysed using Excel statistics package analysis (Microsoft Office Excel) and Origin2021b software. All 27 randomized participants were included in safety and efficacy analysis sets. All statistical tests were performed at a significance level of 0.05 without correction for multiple comparisons or multiple outcomes. Non-parametric tests such as Mann-Whitney U test and Kruskal-Wallis tests were used.

Biomarker levels

Levels are expressed as mean ± SD. In regard to the primary outcome, IL-6 showed decrease in both the control and the treatment groups. However, when the analysis was stratified for steroid administration, IL-6 showed the highest decrease in the N-163 Steroid -ve group, from a baseline value of 7.2 ± 1.2 pg/ml to 2.7 ± 0.03 pg/ ml post intervention and the difference was significant (p-value = 0.01) (Figure 2, 6).

• Download figure
• Open in new tab

Figure 2:

IL-6 showed the most significant decrease in the N-163 Steroid -ve group compared to other groups. (*p-value significance < 0.05)

IL-13 increased in both control groups—from 300.4 ± 114.5 pg/ml at baseline to 550.732 ± 107.95 pg/ml post-intervention in the Steroid -ve group and from 142 ±112.82 pg/ml at baseline to 263.5 ± 99.38 pg/ml post-intervention in the Steroid +ve group. It decreased in both the treatment groups—from 157.76 ± 148.68 pg/ml at baseline to 114.08 ± 81.5 pg/ml post-intervention and from 289.56 ± 232.88 pg/ml at baseline to 255.56 ± 214.13 pg/ml post-intervention. The difference was statistically significant (p-value = 0.006) (Figure 3, 6).

• Download figure
• Open in new tab

Figure 3:

Levels of IL-13 levels showed statistically significant increase in control groups and decrease in treatment groups (*p-value significance < 0.05)

TGF-β levels showed a significant decrease in the N-163 Steroid -ve group, from a baseline value of 3302 ± 1895 pg/ml to 1325.66 ± 517 pg/ml post intervention, which was significantly lower than all the other groups (p-value = 0.02) (Figure 4, 6).

• Download figure
• Open in new tab

Figure 4:

Levels of TGF-β showed significant decrease in the N-163 Steroid -ve group compared to other groups (*p-value significance < 0.05)

Dystrophin levels showed a significant increase in the N-163 Steroid -ve group, from a baseline value of 3.01 ± 1.58 ng/ml to 4.01 ± 1.44ng/ml post intervention, and the N-163 Steroid +ve group went from a baseline value of 3.15 ± 2.43 ng/ml to 3.78 ± 2.17 ng/ml post intervention, which was significantly higher than the control groups (p-value = 0.0009) (Figure 5, 6). The N-163 Steroid -ve group showed higher dystrophin expression than the N-163 Steroid +ve group with the difference being significant (p-value = 0.01). The percentage increase in dystrophin levels in the treatment group was up to 32.8%.

• Download figure
• Open in new tab

Figure 5:

Levels of dystrophin showed significant increase in the N-163 Steroid -ve group compared to other groups (*p-value significance < 0.05)

Haptoglobin did not show much difference pre or post intervention in the treatment groups, but it was marginally increased in the control group (Figure 7). CK increased in the treatment groups (Figure 7). Urine myoglobin increased in the N-163 Steroid +ve group but decreased in all the other groups (Figure 7).

• Download figure
• Open in new tab

Figure 6:

Comprehensive figure of IL-6, IL-13, TGF-β and Dystrophin showing comparison of values between control and treatment group (N-163), pre- and post-intervention (*p-value significance < 0.05)

• Download figure
• Open in new tab

Figure 7:

Levels of Creatinine kinase (CK), Titin, Cystatic-C, Urine myoglobin, Haptoglobin and TNF-α between control and treatment group (N-163), pre- and post-intervention (*p-value significance < 0.05)

Titin and cystatin C decreased in the N-163 Steroid +ve group and the control Steroid +ve group, but the difference was not significant. TNF-α decreased in all the groups except the N-163 Steroid -ve group (Figure 7).

The 6MWT and NSAA did not show any significant differences between the groups (Figure 8). The MRC grading showed slight improvement in 12 out of 18 patients (67%) in the treatment group and only four out of nine (44%) subjects in the control group but it was not statistically significant (p-value = 0.02) (Table 3, Figure 8).

• Download figure
• Open in new tab

Figure 8:

MRC muscle grading, 6MWT and NSAA results between control and treatment group (N-163), pre- and post-intervention (*p-value significance < 0.05)

Anti-inflammatory and anti-fibrotic outcomes

Circulating IL-6 is chronically elevated in individuals with DMD [13], which has been reported to contribute to DMD-associated cognitive dysfunction. IL-6 blockades have been advocated as a therapeutic approach for DMD [14]. In the present study, IL-6 showed highest decrease in the N-163 Steroid -ve group (Figure 2). While IL-6 is an acute inflammatory biomarker [14], IL-13 is a pro-fibrotic biomarker [15] and was significantly decreased (Figure 3). Together with the TGF-β pathway, it is a major proinflammatory and pro-fibrotic cytokine responsible for the chronic inflammatory response leading to replacement of the muscle by scar tissue or fibrosis, resulting in muscle weakness and loss of muscle function [16]. IL-6 values matched that of healthy controls and DMD patients who were treated with corticosteroids [17]. TGF-β levels also showed a significant decrease in the N-163 Steroid -ve group (Figure 4). Dystrophin restoration of 20% expression [18,19] is considered the point of efficacy for a DMD therapy [20] and was found to increase by 32.8% in both the treatment groups (Figure 5) of the present study from baseline. We used serum dystrophin evaluation as recent evidence points to the fact that the lack of dystrophin in the smooth muscle of blood vessels is the major contributing factor to skeletal muscle pathogenesis in DMD and not the dystrophin deficiency in skeletal or cardiac muscle [21]. Dystrophin is expressed in the tunica media of blood vessels, especially in the muscular arteries. It has also been reported that the blood vessel-associated dystrophin is encoded by another gene than the skeletal muscle dystrophin gene [22]. In a mdx mice model study, it was shown that dystrophin which was absent in the blood vessels could be restored by induced genetic expression of full-length human dystrophin (h-dys) and this expression was able to restore the NO-dependent attenuation of α-adrenergic vasoconstriction in the exercising muscles, preventing further exacerbation of muscle fibre necrosis [23]. In the present study, an increase in the plasma levels of dystrophin, which must have been derived from vascular smooth muscle is evidence for the efficacy of beta glucans as a potential adjunct to restore dystrophin in DMD.

Other biochemical markers of relevance

While haptoglobin and urine myoglobin did not show significant differences, the increase in urine myoglobin in the N-163 Steroid +ve group deserves more analysis concerning the underlying mechanism. Greater activity among steroid-treated individuals may place their dystrophin-deficient muscles under greater mechanical stress, predisposing them to further muscle fibre damage and consequent myoglobinuria [24]. While titin and cystatin C decreased in the N-163 steroid +ve group and in the control Steroid +ve group, there was an increase in CK, which is paradoxical, as reports suggest that titin concentration correlates significantly with serum CK concentration [25].

Muscle strength evaluation

There were three evaluations to assess muscle strength and tone, done in a blinded manner by the same physiotherapist at baseline and post intervention. Though the 6MWT and NSAA did not show any significant differences between the groups, MRC grading showed improvement of muscle strength in 67% of the subjects in the treatment group compared to 44% subjects in the control group, which is significant. The limitation of this being a 45-day study is relevant to the muscle-strength and functional evaluations, mandating the need for a longer study and follow-up duration. However, though small, the improvement in MRC grading at 45 days could be again attributed to the immune modulation effects of this disease-modifying supplement. The study shows proof of concept that DMD could be tackled by the N-163 beta glucan from three aspects: decrease in inflammation shown by decreased IL-6 and TNF-α, decrease in fibrosis evident by decreased TGF-β and IL-13 and, more importantly, restoration of dystrophin evident from a 32.8% increase in dystrophin levels. These effects hold regardless of the use or non-use of steroids, which is important, as this safety-proven food supplement can help DMD patients regardless of steroid status.

Chronic inflammation being common to pathogenesis of all muscular dystrophies, immunomodulatory treatment may benefit patients with diverse types of muscular dystrophy [26]. Further, modulating the inflammatory response and inducing immunological tolerance to de novo dystrophin expression is critical to the success of dystrophin-replacement therapies [27]. The need to evaluate the muscles involved in respiratory function and myocardium should be mentioned here, as they are the cause of mortality in most of the DMD patients [1]. Though other dystrophies, such as limb girdle muscular dystrophy (LGMD), do not involve respiratory or cardiac muscles, inflammatory overactivity is the common pathophysiology among types of muscular dystrophy [26]. Once proven efficacious for DMD, extending the beneficial application of the N-163 beta glucans to other dystrophies such as LGMD can be considered.

DMD is a rare genetic disease with a maximum life expectancy of up to fourth decade, with the majority of victims dying in their late twenties to thirties. The average lifespan at birth, which was 20+ years for those born in or before 1970, has gradually increased by 10∼15 years for those born and diagnosed with DMD in the 1980s and 1990s. This increase is attributed to better or early ventilatory assistance, steroid usage and cardiac care [28,29], which are only supportive interventions. With the gene therapies approved recently, there is a hope of additional progress and increase in lifespan [30]. Though these gene therapies (such as exon skipping) address the root cause by splicing out selected exons from the pre-mRNA at or next to the mutation site, generating a translatable transcript from the mutant dystrophin gene leading to dystrophin expression [30, 31], they are still marred by challenges such as delivery of gene-editing components throughout the musculature and mitigation of possible immune responses [32]. The current need, therefore, is to modulate the immune system and control the inflammation and ensuing fibrosis to delay the progression of the disease. The earlier usage of steroids in a regular manner was later changed to intermittent usage [33] with regimens varying between institutes; now, newer steroids with lesser adverse effects are in various stages of progress towards clinical applications [34]. In this background, the safety of this N-163-produced beta glucan food supplement without adverse reactions is to be considered an indispensable value addition. Targeting the inflammation component (the criteria for selecting this supplement for this study) having yielded beneficial outcomes, additional studies on this characteristic could be of value to possibly extending their application for other neuroinflammatory diseases, such as multiple sclerosis.

The limitations of the study include uneven distribution of subjects, broad age range (5-19 years) and short follow-up (only 45 days); improvements in muscle function over the course of the study showed variability that may have been due to the level of sensitivity to change of functional assessments during the disease progression in the age group. Among the 27 subjects, two-thirds were ambulatory and the remaining non-ambulatory; the evaluation criteria differences must be kept in mind, which may show equivalent quantification among all DMD patients at different stages of disease severity when non-invasive myograms to measure the individual muscles accurately could be undertaken. Further, the steroid dose was not uniform and fell into a broad range (6-24 mg). Also, the consumption of steroids vs those who did not consume them or those who had stopped steroids after an initial duration of consumption, as well as regimen variation, are to be considered while interpreting the outcomes. All these aspects mandate the need for larger randomized clinical trials of longer duration to validate this supplement as a treatment.